Hormone pill slows prostate cancer growth

2012-06-02 19:57
Prostate cancer drug

Prostate cancer drug

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Chicago - A hormone-blocking pill approved last year for some men with advanced prostate cancer now also seems to help a wider group of men who were given it sooner in the course of treating their disease.

In a study of nearly 1 100 such men, Johnson & Johnson's Zytiga doubled the time patients lived without their cancer getting worse.

The drug also seems to be improving survival, but it will take longer follow-up to know for sure. Independent monitors stopped the study once it was clear the drug was helping and let men who had been getting dummy pills to switch to Zytiga. At that point - after a median treatment time of two years - 34% of men on dummy pills had died versus 27% of those taking Zytiga.

"Our hope is that this can become a new option" for up to 30 000 men each year in the United States, said study leader Dr Charles Ryan of the University of California, San Francisco.

He gave results Saturday at a meeting in Chicago of the American Society of Clinical Oncology.

Prostate cancer is the most common cancer in American men. In the United States alone, more than 240 000 new cases and 28 000 deaths from the disease are expected this year. Many cases don't need treatment because the cancer grows so slowly it isn't a threat. For men who choose treatment when the disease is still confined to the prostate, surgery and radiation are common options.

Once it spreads, though, it often is treated with drugs that curb testosterone. They block about 90% of the hormone, "but that remaining 10% can still stimulate the cancer and cause death from the disease," Ryan said.

Zytiga blocks virtually all of it - "it's really complete chemical castration," said another study leader, Duke University's Dr Daniel George.

The drug won federal approval last year for men with advanced prostate cancer whose disease had worsened despite treatment with standard hormones and chemotherapy. The new study tested it earlier in the course of illness - in men with advanced prostate cancer who have not yet received chemotherapy.

Doubles life expectancy

Researchers gave more than 1 000 patients in the US, Canada, Europe and Australia either Zytiga or dummy pills plus a steroid that also is widely used to treat such cases.

When the study was stopped, the median time until cancer worsened in the group getting dummy pills was about eight months. Those on Zytiga were faring much better, so doctors can only estimate the time it is taking for their cancers to worsen - at least 16 months, Ryan said.

There were more cases of high blood pressure, fluid retention and heart problems among men on Zytiga. Like other hormone-blockers, it can cause hot flashes and sexual problems. And Zytiga is expensive - $5 500 a month in the United States.

The study was sponsored by the drug's maker, Johnson & Johnson's Janssen division, and some study leaders have financial ties to the company. The company plans to seek approval later this year to sell the drug for men like those in the new study.

Michael Wells, 65, a retired construction worker from Oakville in California's Napa Valley, was diagnosed nearly 12 years ago with prostate cancer that had spread to his bones. Standard hormone and radiation treatments kept it in check for many years, but when it started growing, he enrolled in the study.

Zytiga gave him high blood pressure but other than that, "I have not noticed any difference taking the pills - I've always had hot flashes" on prostate medicines, he said.

He has now been on Zytiga for nearly three years, and scans show his cancer is in check.

"It's worked for me, and it's still working," Wells said.

Read more on:    johnson & johnson  |  us  |  health  |  research  |  cancer

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

linking and moving

2015-04-22 07:36

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
1 comment
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.